Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia.
about
Use of Cell-Penetrating Peptides in Dendritic Cell-Based VaccinationAllogeneic tumor cell vaccines: the promise and limitations in clinical trialsClinical trials of dendritic cell-based cancer vaccines in hematologic malignanciesImmunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemiaA novel cancer vaccine strategy based on HLA-A*0201 matched allogeneic plasmacytoid dendritic cells.Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemiaB-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21Deficiency of C5aR prolongs renal allograft survival.Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC.Trial watch: Dendritic cell-based interventions for cancer therapyDendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivoTargets and strategies for T-cell based vaccines in patients with B-cell chronic lymphocytic leukemia.Dendritic cell vaccines for leukemia patients.Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia.Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines.Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy.Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells.Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naïve cytotoxic priming and anti-tumour therapy.Peptide vaccines for patients with acute myeloid leukemia.Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia.Dendritic cell preparation for immunotherapeutic interventions.Breaking immunotolerance of tumors: a new perspective for dendritic cell therapy.Dendritic cell vaccine against leukemia: advances and perspectives.Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia.Quantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia.Cellular immunotherapy of cancer: an overview and future directions.Progress of dendritic cell-based cancer vaccines for patients with hematological malignancies.Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.Dendritic Cell Therapies for Hematologic Malignancies.Allogeneic tumor vaccine produced by electrofusion between osteosarcoma cell line and dendritic cells in the induction of antitumor immunity.Large-scale generation of autologous dendritic cells for immunotherapy in patients with acute myeloid leukemia.
P2860
Q26764861-D072868B-BCFD-4C2C-AFC9-C82207F33C7DQ26852333-F4D07449-BBD1-46F7-A6AD-B4A4EDF49B6CQ26864603-ECDC61E6-F7DE-4328-8FC8-FB216F955811Q27001318-9094F05A-DE6D-4F1E-BB68-8CBB5483F06DQ33573323-52624B3A-C6CA-4233-9E0F-30F22FD457A9Q34011555-34C3151B-D312-4BAB-81E6-E3B6A6F7C2D4Q34048170-F8BBF539-00BF-4454-A523-D56C92876A35Q34124191-23B2B7B8-B64F-414C-A18A-241E841AF1FDQ34531834-AB4CEAFB-BC4B-4A1B-BD44-28312B8B52E0Q36388529-B22DD5C8-9768-44C4-8891-7FCBFC25311BQ36407174-D7EF632F-0F3A-4923-B048-2A42514919D9Q36637647-189E30FD-8D50-4B52-84F0-4D71DC761308Q36752018-332094A3-7EC8-4AE8-96EC-2DE0118B3DD1Q37088532-4D98DF5B-F055-4DA0-ADD6-B51685F39126Q37181792-325B7C41-E6AF-4642-9D71-5FCC561B9DFBQ37318762-441CE307-28C5-4E6D-BADC-D7847041A96CQ37378009-903F1697-407C-4771-ADB4-04E39EE7948AQ37519014-0F3A8F3F-EB01-47ED-B103-48EA7B1CE7DEQ37608316-2297B6A9-B8FE-43A4-8EB8-55A7491A6ADAQ37773237-AAFE8587-1AD0-4063-B0F7-1D72B5429296Q37773266-FA099CF5-403A-4B94-8F27-357E8AB09E2EQ38185156-0F072663-071A-4A52-ABEB-B7F4FA367927Q38210813-2DCD91E4-1F3D-461E-B42C-95743E3A34D0Q38259446-F63A35A5-1078-4EA5-939A-AB0BF89E7B13Q38294373-1E273C3E-E0A2-4C1A-AF84-E693438E8C42Q38673161-3931FC85-15A7-47DB-BA22-17E91924EF5CQ38847756-37F81DA8-3FDA-4DDD-B985-40AC4E0F1A58Q39265240-E93C9F63-D940-411A-A1C8-66BA3C4616B0Q39289930-4F33212E-B696-4230-838F-E5996DAB0FDFQ40063997-322F3F5D-8AF7-4B2C-AC9D-D89531AB1196Q45789544-800720B5-EFE1-463E-BE14-92C74F4FCADE
P2860
Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Allogeneic dendritic cells pul ...... chronic lymphocytic leukemia.
@en
Allogeneic dendritic cells pul ...... chronic lymphocytic leukemia.
@nl
type
label
Allogeneic dendritic cells pul ...... chronic lymphocytic leukemia.
@en
Allogeneic dendritic cells pul ...... chronic lymphocytic leukemia.
@nl
prefLabel
Allogeneic dendritic cells pul ...... chronic lymphocytic leukemia.
@en
Allogeneic dendritic cells pul ...... chronic lymphocytic leukemia.
@nl
P2093
P2860
P50
P921
P356
P1433
P1476
Allogeneic dendritic cells pul ...... l chronic lymphocytic leukemia
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403860
P577
2005-09-01T00:00:00Z